{
    "nct_id": "NCT04437511",
    "official_title": "Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease",
    "inclusion_criteria": "* Gradual and progressive change in memory function reported by participants or informants for â‰¥ 6 months\n* MMSE score of 20 to 28 (inclusive) at baseline\n* Meet 18F flortaucipir PET scan (central read) criteria - does not apply to safety cohort\n* Meet 18F florbetapir PET scan (central read) criteria\n* Have a study partner who will provide written informed consent to participate\nHealthy volunteers allowed\nMust have minimum age of 60 Years\nMust have maximum age of 85 Years",
    "exclusion_criteria": "* Contraindication to MRI or PET scans\n* Current treatment with immunoglobulin G (IgG) therapy",
    "miscellaneous_criteria": ""
}